<DOC>
	<DOC>NCT00752232</DOC>
	<brief_summary>The study is to evaluate the safety, tolerability and whether there is an immune system response to multiple doses of ACC-001 with or without the use of a substance that may increase the response to the drug.</brief_summary>
	<brief_title>Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<criteria>Diagnosis of mild to moderate Alzheimer's Disease Mini Mental Status Exam (MMSE) of 1626 Significant Neurological Disease Major Psychiatric Disorder Clinically significant systemic illness</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Phase IIa</keyword>
	<keyword>multiple ascending dose study of ACC-001</keyword>
</DOC>